JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

Начало・Списък с акции・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Отворен

СекторЗдравеопазване

2.99 1.01

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.93

Максимум

3.03

Ключови измерители
By Trading Economics
Приходи	-5.9M 247K
Продажби	5.1M 62M
Марж на печалбата	0.395
Служители	181
EBITDA	-6.1M 7.4M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+124.36% upside

Дивиденти
By Dow Jones
Следващи печалби	6.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-50M 838M
Предишно отваряне	1.98
Предишно затваряне	2.99

Настроения в новините

By Acuity

64%

36%

328 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

2.345 / N/A Подкрепа & съпротива

Akebia Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.10.2025 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22.10.2025 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22.10.2025 г., 21:20 ч. UTC

Печалби

Correction to IBM 3Q Sales Jump Article

22.10.2025 г., 20:57 ч. UTC

Печалби

SAP Posts Higher 3Q Revenue, Operating Profit

22.10.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.10.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22.10.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22.10.2025 г., 23:15 ч. UTC

Печалби

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22.10.2025 г., 22:28 ч. UTC

Пазарно говорене

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22.10.2025 г., 22:02 ч. UTC

Печалби

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22.10.2025 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22.10.2025 г., 21:58 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22.10.2025 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22.10.2025 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22.10.2025 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22.10.2025 г., 21:47 ч. UTC

Печалби

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22.10.2025 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22.10.2025 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22.10.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22.10.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22.10.2025 г., 21:28 ч. UTC

Пазарно говорене

Печалби

Correction to Alcoa Tariff Market Talk

22.10.2025 г., 21:25 ч. UTC

Печалби

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22.10.2025 г., 21:17 ч. UTC

Печалби

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22.10.2025 г., 21:09 ч. UTC

Пазарно говорене

Печалби

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22.10.2025 г., 21:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

22.10.2025 г., 20:59 ч. UTC

Печалби

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22.10.2025 г., 20:51 ч. UTC

Печалби

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.10.2025 г., 20:44 ч. UTC

Печалби

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Сравнение с други в отрасъла

Ценова промяна

Akebia Therapeutics Inc Прогноза

Ценова цел

By TipRanks

124.36% нагоре

12-месечна прогноза

Среден 7 USD 124.36%

Висок 8 USD

Нисък 6 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Akebia Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Akebia Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

2.345 / N/AПодкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

328 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.